Education
About Us
Working with TipRanks
Follow Us
Lifeward (LFWD)
NASDAQ:LFWD
Top Page
Lifeward
(NASDAQ:LFWD)
Rating:43Neutral
Price Target:―
Positive Factors
Growth potential
Robust pipeline bodes well for long-term growth.
Partnerships
Recent developments help diversify Lifeward's business through an exclusive partnership with CorLife and an expanded distribution agreement with MYOLYN.
Negative Factors
Financial performance
The company reported a net loss of $1.73 per share, compared to consensus estimated net loss of $0.31 per share.
Reimbursement challenges
The company continues to experience longer than expected time to receive CMS reimbursement.
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.87M
Dividend YieldN/A
Average Volume (3M)1.26M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth85.24%
EPS Growth-27.93%
CountryUS
Employees80
SectorHealthcare
Sector Strength38
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.44
Shares Outstanding15,602,266
10 Day Avg. Volume298,588
30 Day Avg. Volume1,257,141
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)2.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit18.22
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$3.00Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lifeward Business Overview & Revenue Model
Company Descriptionnull
How the Company Makes Moneynull
Lifeward Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: -51.39%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
While Lifeward faced challenges such as revenue decline and supply constraints, significant progress was made in strategic partnerships, product approvals, and operational efficiencies. This suggests a positive outlook for the company's future performance.Q1-2025 Updates
Positive Updates
FDA Clearance of ReWalk 7
Lifeward received FDA clearance for the ReWalk 7, the next generation exoskeleton, marking significant progress in their product offerings.
Partnership with CorLife
Lifeward entered into a partnership with CorLife to improve access in the workers' compensation segment, aiming to drive profitable growth.
Expansion in Germany
The ReWalk contract with BARMER in Germany was expanded, potentially setting a model for working with other insurers in the region.
Increase in Qualified ReWalk Leads
The pipeline of qualified ReWalk leads in the US increased by over 70% in the past two quarters.
AlterG Product Growth
AlterG products grew by 19% and 17% in the last two quarters, with a strong first quarter performance driven by international sales.
Reduction in Operating Loss
Lifeward achieved a 25% reduction in operating loss in Q1, with expectations for further reductions as revenue grows.
Negative Updates
Q1 Revenue Decline
Revenues were $5 million in Q1 2025, down $300,000 from the previous year, attributed to catch-up revenues in 2024.
Temporary Supply Constraints
AlterG experienced temporary supply constraints due to a transition to a contract manufacturer, limiting potential sales growth.
Lower Gross Margins
GAAP gross margin was 42.2% in Q1 2025, below expectations due to volume and mix of ReWalk products and transitional costs for AlterG.
Challenges with DME MACs
Complexity in processing claims with DME MACs continues to be an issue, although some progress in standardization was noted.
Company Guidance
During the Q1 2025 earnings call, Lifeward Inc. provided detailed guidance, emphasizing several key metrics. The company reported Q1 revenues of $5 million, down from $5.3 million in Q1 2024 due to a $500,000 catch-up revenue from Medicare in the previous year. Despite this, Lifeward highlighted significant operational progress, including over 120 qualified ReWalk leads in the US, a 70% increase over two quarters, and 36 ReWalk rentals, primarily in Germany, indicating future sales. AlterG sales grew by 19% and 17% in the last two quarters. The company achieved a 25% reduction in Q1 operating loss and expects further reductions as savings phase in. GAAP gross margin rose to 42.2% from 26.4% in Q1 2024, while operating expenses decreased to $7 million from $7.9 million. Lifeward reaffirmed its 2025 sales guidance between $28 million to $30 million, anticipating a Q4 adjusted operating loss of approximately $1 million.Lifeward Financial Statement Overview
Summary
Lifeward is experiencing strong revenue growth but faces significant profitability challenges. The company has a healthy balance sheet with a high equity ratio, though negative cash flows and earnings pose risks. Future improvements in operational efficiency are crucial for financial sustainability.Income Statement
Lifeward's revenue has shown strong growth, from $4.4 million in 2020 to $25.7 million in 2024, marking a significant upward trajectory. However, the company has consistently posted negative EBIT and net income, indicating operational inefficiencies and challenges in achieving profitability. The gross profit margin is improving but remains offset by high operating expenses.35
Negative
Balance Sheet
The company has a healthy stockholders' equity position, which is significantly higher than its total liabilities, resulting in a low debt-to-equity ratio. However, the return on equity is negative due to consistent net losses, highlighting a risk of financial instability despite the strong equity base.45
Neutral
Cash Flow
Lifeward experiences negative operating and free cash flow, indicating reliance on external financing for operations. The free cash flow growth rate is negative, showing challenges in converting revenue to cash. Cash flow ratios to net income are unfavorable, reflecting operational cash deficits.40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.66M | 13.85M | 5.51M | 5.97M | 4.39M |
| Gross Profit | 8.22M | 4.45M | 1.91M | 2.90M | 2.19M |
| EBITDA | -19.55M | -21.77M | -18.90M | -12.39M | -11.73M |
| Net Income | -28.94M | -22.13M | -19.57M | -12.74M | -12.98M |
Balance Sheet | |||||
| Total Assets | 30.49M | 63.19M | 74.24M | 94.75M | 28.07M |
| Cash, Cash Equivalents and Short-Term Investments | 6.75M | 28.08M | 67.90M | 88.34M | 20.35M |
| Total Debt | 880.00K | 1.90M | 897.00K | 1.06M | 1.58M |
| Total Liabilities | 11.64M | 16.68M | 6.07M | 5.37M | 6.29M |
| Stockholders Equity | 18.85M | 46.51M | 68.17M | 89.38M | 21.77M |
Cash Flow | |||||
| Free Cash Flow | -21.72M | -20.75M | -17.92M | -11.52M | -12.66M |
| Operating Cash Flow | -21.72M | -20.67M | -17.89M | -11.47M | -12.59M |
| Investing Cash Flow | 0.00 | -18.15M | -25.00K | -47.00K | -73.00K |
| Financing Cash Flow | 0.00 | -992.00K | -2.50M | 79.51M | 16.72M |
Lifeward Technical Analysis
Negative
0.70
Price Trends
0.93
Negative
1.21
Negative
1.56
Negative
Market Momentum
-0.05
Negative
37.50
Neutral
7.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.93, and below the 200-day MA of 1.56, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 37.50 is Neutral, neither overbought nor oversold. The STOCH value of 7.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 60 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifeward Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.35B | 0.50 | -65.61% | 2.47% | 15.28% | 1.44% | |
46 Neutral | $20.62M | ― | 38.80% | ― | -41.98% | 88.34% | |
43 Neutral | $10.87M | ― | -93.11% | ― | 85.24% | -27.93% | |
42 Neutral | $26.04M | ― | -99.84% | ― | ― | 10.23% | |
40 Underperform | $26.05M | ― | 14.03% | ― | -29.82% | -2.57% | |
39 Underperform | $54.81M | ― | -201.88% | ― | ― | ― | |
31 Underperform | $946.67K | ― | -231.27% | ― | ― | 35.08% |
* Healthcare Sector Average
Performance Comparison
LFWD
Lifeward
0.70
-2.98
-80.98%
CCM
Concord Medical Services
6.00
-0.81
-11.89%
NNVC
NanoViricides
1.58
-0.44
-21.78%
UNBX
Unity Biotechnology
0.06
-1.29
-95.56%
ALUR
Allurion Technologies
2.76
-16.74
-85.85%
IXHL
Incannex Healthcare Limited Sponsored ADR
0.38
-1.66
-81.37%
Lifeward Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Lifeward Announces Termination of Chief Sales Officer
Negative
Apr 14, 2025
Lifeward has announced that Charles Remsberg’s role as Chief Sales Officer will be terminated without cause, effective May 30, 2025. This decision, disclosed in the company’s annual report, ensures Mr. Remsberg will receive severance and benefits as per his employment agreement, potentially impacting the company’s sales leadership and strategy.
Spark’s Take on LFWD Stock
According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.
Lifeward’s stock is rated low primarily due to ongoing financial challenges, despite strong revenue growth. Technical indicators suggest a current downtrend, and valuation metrics are unattractive due to negative earnings. While strategic initiatives show promise, the high risks associated with financial instability and operational inefficiencies are significant concerns.
To see Spark’s full report on LFWD stock, click here.
Executive/Board Changes
Rewalk Robotics CEO Larry Jasinski to Step Down
Neutral
Feb 20, 2025
On February 19, 2025, Rewalk Robotics announced that Larry Jasinski will step down as CEO and board member by the end of the second quarter of 2025. Jasinski’s departure will be considered a termination without cause, and the company plans to finalize a separation agreement with him before his exit.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.